Pub Date : 2016-10-06DOI: 10.1177/1715163516671747
Yazid N. Al Hamarneh, S. Houle, R. Padwal, R. Tsuyuki
The Canadian Hypertension Education Program (CHEP) has been preparing and publishing guidelines for diagnosis and management of hypertension since 1999.1 The 2016 guidelines,2 released earlier this year, mark the 18th yearly production and update of evidence to date in the area of hypertension. Those guidelines, among other Hypertension Canada activities, can be considered as major contributors to the high levels of awareness and control of hypertension in Canada.3,4 Indeed, it has been reported that Canada has higher levels of awareness, treatment and control and lower prevalence of hypertension when compared with the United States and England.3
{"title":"Hypertension Canada’s 2016 Canadian Hypertension Education Program guidelines for pharmacists","authors":"Yazid N. Al Hamarneh, S. Houle, R. Padwal, R. Tsuyuki","doi":"10.1177/1715163516671747","DOIUrl":"https://doi.org/10.1177/1715163516671747","url":null,"abstract":"The Canadian Hypertension Education Program (CHEP) has been preparing and publishing guidelines for diagnosis and management of hypertension since 1999.1 The 2016 guidelines,2 released earlier this year, mark the 18th yearly production and update of evidence to date in the area of hypertension. Those guidelines, among other Hypertension Canada activities, can be considered as major contributors to the high levels of awareness and control of hypertension in Canada.3,4 Indeed, it has been reported that Canada has higher levels of awareness, treatment and control and lower prevalence of hypertension when compared with the United States and England.3","PeriodicalId":46612,"journal":{"name":"Canadian Pharmacists Journal","volume":"149 1","pages":"337 - 344"},"PeriodicalIF":1.5,"publicationDate":"2016-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1715163516671747","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"65467409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-10-06DOI: 10.1177/1715163516671744
Sarah Drost, A. Massicotte
Antidepressant use in North America is on the rise. From 2007 to 2011, antidepressants were the most commonly used medication class by Canadian women aged 25 to 79 years and among the top 5 classes of drugs used by men aged 25 to 64 years.1 Selective serotonin reuptake inhibitors (SSRIs; e.g., citalopram, paroxetine, sertraline) are one of the most widely used classes of antidepressants because of their efficacy, favourable side effect profile and broad indications for use.2 In the past decade, more attention has been paid to the adverse effects of medications on bone health. Glucocorticoids, aromatase inhibitors (e.g., anastrazole, letrozole, exemestane), thiazolidinediones or “glitazones” (e.g., pioglitazone) and proton pump inhibitors (e.g., pantoprazole, omeprazole), among others, are suspected contributors to fractures.3 There is evidence indicating that SSRIs may also be implicated.3 In patients aged 66 years and older, current exposure to SSRIs has been associated with hip fractures compared with no antidepressant exposure (adjusted odds ratio [aOR]; 2.4; 95% CI: 2.0-2.7).4 One-third of women and one-fifth of men in Canada will experience an osteoporotic fracture during their lifetime. In 2010, osteoporosis and fractures cost the Canadian health care system upwards of 2.3 billion dollars.5 Fractures can cause a loss of long-term mobility and increase the risk of institutionalization. A prospective observational cohort of older adults showed that 12 months after a hip fracture, only half of patients regained their prefracture mobility level and only one-third of those who were previously mobile without an aid regained full mobility.6 A Canadian cohort (2001-2006) revealed that 12 months after a hip fracture, 24% of adults aged 75 years and older who were previously living in the community required institutionalization.7 However, that risk was much lower in patients aged 60 to 74 years, in whom only 14% of men and 4% of women required a transfer to a long-term care institution.7 Fractures are also associated with mortality, with 28% of women and 37% of men who experience a hip fracture dying within a year.5 It is therefore increasingly important to quantify the association between SSRIs and bone health. This review will discuss the current evidence that explores their association with an increased fracture risk.
{"title":"Are selective serotonin reuptake inhibitors associated with fractures?","authors":"Sarah Drost, A. Massicotte","doi":"10.1177/1715163516671744","DOIUrl":"https://doi.org/10.1177/1715163516671744","url":null,"abstract":"Antidepressant use in North America is on the rise. From 2007 to 2011, antidepressants were the most commonly used medication class by Canadian women aged 25 to 79 years and among the top 5 classes of drugs used by men aged 25 to 64 years.1 Selective serotonin reuptake inhibitors (SSRIs; e.g., citalopram, paroxetine, sertraline) are one of the most widely used classes of antidepressants because of their efficacy, favourable side effect profile and broad indications for use.2 \u0000 \u0000In the past decade, more attention has been paid to the adverse effects of medications on bone health. Glucocorticoids, aromatase inhibitors (e.g., anastrazole, letrozole, exemestane), thiazolidinediones or “glitazones” (e.g., pioglitazone) and proton pump inhibitors (e.g., pantoprazole, omeprazole), among others, are suspected contributors to fractures.3 There is evidence indicating that SSRIs may also be implicated.3 In patients aged 66 years and older, current exposure to SSRIs has been associated with hip fractures compared with no antidepressant exposure (adjusted odds ratio [aOR]; 2.4; 95% CI: 2.0-2.7).4 \u0000 \u0000One-third of women and one-fifth of men in Canada will experience an osteoporotic fracture during their lifetime. In 2010, osteoporosis and fractures cost the Canadian health care system upwards of 2.3 billion dollars.5 Fractures can cause a loss of long-term mobility and increase the risk of institutionalization. A prospective observational cohort of older adults showed that 12 months after a hip fracture, only half of patients regained their prefracture mobility level and only one-third of those who were previously mobile without an aid regained full mobility.6 A Canadian cohort (2001-2006) revealed that 12 months after a hip fracture, 24% of adults aged 75 years and older who were previously living in the community required institutionalization.7 However, that risk was much lower in patients aged 60 to 74 years, in whom only 14% of men and 4% of women required a transfer to a long-term care institution.7 Fractures are also associated with mortality, with 28% of women and 37% of men who experience a hip fracture dying within a year.5 It is therefore increasingly important to quantify the association between SSRIs and bone health. This review will discuss the current evidence that explores their association with an increased fracture risk.","PeriodicalId":46612,"journal":{"name":"Canadian Pharmacists Journal","volume":"149 1","pages":"332 - 336"},"PeriodicalIF":1.5,"publicationDate":"2016-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1715163516671744","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"65467318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-10-06DOI: 10.1177/1715163516672832
Meagen M Rosenthal, Z. Austin, R. Tsuyuki
The practice of pharmacy has seen major changes in the past decade. Today, pharmacists from coast to coast can extend prescriptions and make therapeutic substitutions. Many pharmacists can also provide influenza vaccinations and in some cases initiate drug therapies (i.e., prescribe). However, it has also been well established that the integration of many of these services by pharmacists into practice has been slow and incomplete. As pharmacy regulatory and advocacy groups continue to push for pharmacists’ larger role within the health care system, these efforts are hampered by the lack of widespread adoption and integration of these services within practice. Therefore, we need to more carefully consider why pharmacy practice change has been so challenging. In 2010, we wrote a commentary titled “Are Pharmacists the Ultimate Barrier to Pharmacy Practice Change?” In that article, we suggested that pharmacists’ personality traits, including lack of confidence, fear of new responsibility, paralysis in the face of ambiguity, need for approval and risk aversion, were the heretofore unspoken barriers to practice change. Using this commentary as a starting point, the purpose of this editorial is to discuss the issue of whether it is our innate personality traits (“nature”) or our professional pharmacy culture (“nurture”) that holds us back.
{"title":"Barriers to pharmacy practice change","authors":"Meagen M Rosenthal, Z. Austin, R. Tsuyuki","doi":"10.1177/1715163516672832","DOIUrl":"https://doi.org/10.1177/1715163516672832","url":null,"abstract":"The practice of pharmacy has seen major changes in the past decade. Today, pharmacists from coast to coast can extend prescriptions and make therapeutic substitutions. Many pharmacists can also provide influenza vaccinations and in some cases initiate drug therapies (i.e., prescribe). However, it has also been well established that the integration of many of these services by pharmacists into practice has been slow and incomplete. As pharmacy regulatory and advocacy groups continue to push for pharmacists’ larger role within the health care system, these efforts are hampered by the lack of widespread adoption and integration of these services within practice. Therefore, we need to more carefully consider why pharmacy practice change has been so challenging. In 2010, we wrote a commentary titled “Are Pharmacists the Ultimate Barrier to Pharmacy Practice Change?” In that article, we suggested that pharmacists’ personality traits, including lack of confidence, fear of new responsibility, paralysis in the face of ambiguity, need for approval and risk aversion, were the heretofore unspoken barriers to practice change. Using this commentary as a starting point, the purpose of this editorial is to discuss the issue of whether it is our innate personality traits (“nature”) or our professional pharmacy culture (“nurture”) that holds us back.","PeriodicalId":46612,"journal":{"name":"Canadian Pharmacists Journal","volume":"149 1","pages":"317 - 319"},"PeriodicalIF":1.5,"publicationDate":"2016-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1715163516672832","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"65467457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-10-06DOI: 10.1177/1715163516671334
Ariane Cantin, Alexandre Lahaie, Bojan Odobasic, Marie-Philip Tremblay, Dana Wazzan, Stéphanie Caron, C. Leblanc, J. Martineau, L. Lalonde
Background: The ACO Program (Programme ACO), a continuous quality improvement program (CQIP) in anticoagulation therapy, was offered in community pharmacies as a pilot project. Objective: To evaluate the participants’ appreciation for the various activities of the program. Methods: Participants had access to training activities, including an audit with feedback, online training activities (OTA), clinical tools and support from facilitators. Cognitive behavioural learning determinants were evaluated before and 5 months after the beginning of the program. Participants’ satisfaction and perception were documented via online questionnaires and a semistructured interview. Results: Of the 52 pharmacists in the ACO Program, 47 participated in this evaluation. Seventy-seven percent of the participants completed at least 1 OTA and 6% published on the forum. The feeling of personal effectiveness rose from 8.01 (7.67-8.35) to 8.62 (8.24-8.99). The audit and feedback, as well as the high-quality OTA and their lecturers, were the most appreciated elements. Discussion: There was a high OTA participation rate. The facilitators seemed to play a key role in the CQIP. The low level of participation in the forum reflects the known phenomenon of social loafing. Technical difficulties affecting the platform and data collection for the audit with feedback constituted limitations. Conclusion: The CQIP in anticoagulation therapy is appreciated by community pharmacists and is associated with an improved feeling of personal effectiveness.
{"title":"Evaluation of a continuous quality improvement program in anticoagulant therapy","authors":"Ariane Cantin, Alexandre Lahaie, Bojan Odobasic, Marie-Philip Tremblay, Dana Wazzan, Stéphanie Caron, C. Leblanc, J. Martineau, L. Lalonde","doi":"10.1177/1715163516671334","DOIUrl":"https://doi.org/10.1177/1715163516671334","url":null,"abstract":"Background: The ACO Program (Programme ACO), a continuous quality improvement program (CQIP) in anticoagulation therapy, was offered in community pharmacies as a pilot project. Objective: To evaluate the participants’ appreciation for the various activities of the program. Methods: Participants had access to training activities, including an audit with feedback, online training activities (OTA), clinical tools and support from facilitators. Cognitive behavioural learning determinants were evaluated before and 5 months after the beginning of the program. Participants’ satisfaction and perception were documented via online questionnaires and a semistructured interview. Results: Of the 52 pharmacists in the ACO Program, 47 participated in this evaluation. Seventy-seven percent of the participants completed at least 1 OTA and 6% published on the forum. The feeling of personal effectiveness rose from 8.01 (7.67-8.35) to 8.62 (8.24-8.99). The audit and feedback, as well as the high-quality OTA and their lecturers, were the most appreciated elements. Discussion: There was a high OTA participation rate. The facilitators seemed to play a key role in the CQIP. The low level of participation in the forum reflects the known phenomenon of social loafing. Technical difficulties affecting the platform and data collection for the audit with feedback constituted limitations. Conclusion: The CQIP in anticoagulation therapy is appreciated by community pharmacists and is associated with an improved feeling of personal effectiveness.","PeriodicalId":46612,"journal":{"name":"Canadian Pharmacists Journal","volume":"149 1","pages":"352 - 361"},"PeriodicalIF":1.5,"publicationDate":"2016-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1715163516671334","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"65467306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-10-06DOI: 10.1177/1715163516671968
K. Grindrod, M. Beazely
{"title":"Fitting naloxone into community pharmacy practice","authors":"K. Grindrod, M. Beazely","doi":"10.1177/1715163516671968","DOIUrl":"https://doi.org/10.1177/1715163516671968","url":null,"abstract":"","PeriodicalId":46612,"journal":{"name":"Canadian Pharmacists Journal","volume":"149 1","pages":"329 - 331"},"PeriodicalIF":1.5,"publicationDate":"2016-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1715163516671968","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"65467421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-10-03DOI: 10.1177/1715163516671745
S. Houle, T. Charrois, F. McAlister, M. Kolber, Meagen M Rosenthal, R. Lewanczuk, N. Campbell, R. Tsuyuki
Background: To be sustainable, pharmacists providing direct patient care must receive appropriate payment for these services. This prespecified substudy of the RxACTION trial (a randomized trial of pharmacist prescribing vs usual care in patients with above-target blood pressure [BP]) aimed to determine if BP reduction achieved differed between patients whose pharmacist was paid by pay-for-performance (P4P) vs fee-for-service (FFS). Methods: Within RxACTION, patients with elevated BP assigned to the pharmacist prescribing group were further randomized to P4P or FFS payment for the pharmacist. In FFS, pharmacists received $150 for the initial visit and $75 for follow-up visits. P4P included FFS payments plus incentives of $125 and $250 for each patient who reached 50% and 100% of the BP target, respectively. The primary outcome was difference in change in systolic BP between P4P and FFS groups. Results: A total of 89 patients were randomized to P4P and 92 to the FFS group. Patients’ average (SD) age was 63.0 (13.2) years, 49% were male and 76% were on antihypertensive drug therapy at baseline, taking a median of 2 (interquartile range = 1) medications. Mean systolic BP reductions in the P4P and FFS groups were 19.7 (SD = 18.4) vs 17.0 (SD = 16.4) mmHg, respectively (p = 0.47 for the comparison of deltas and p = 0.29 after multivariate adjustment). Conclusions: This trial of pharmacist prescribing found substantial reductions in systolic BP among poorly controlled hypertensive individuals but with no appreciable difference when pharmacists were paid by P4P vs FFS.
{"title":"Pay-for-performance remuneration for pharmacist prescribers’ management of hypertension","authors":"S. Houle, T. Charrois, F. McAlister, M. Kolber, Meagen M Rosenthal, R. Lewanczuk, N. Campbell, R. Tsuyuki","doi":"10.1177/1715163516671745","DOIUrl":"https://doi.org/10.1177/1715163516671745","url":null,"abstract":"Background: To be sustainable, pharmacists providing direct patient care must receive appropriate payment for these services. This prespecified substudy of the RxACTION trial (a randomized trial of pharmacist prescribing vs usual care in patients with above-target blood pressure [BP]) aimed to determine if BP reduction achieved differed between patients whose pharmacist was paid by pay-for-performance (P4P) vs fee-for-service (FFS). Methods: Within RxACTION, patients with elevated BP assigned to the pharmacist prescribing group were further randomized to P4P or FFS payment for the pharmacist. In FFS, pharmacists received $150 for the initial visit and $75 for follow-up visits. P4P included FFS payments plus incentives of $125 and $250 for each patient who reached 50% and 100% of the BP target, respectively. The primary outcome was difference in change in systolic BP between P4P and FFS groups. Results: A total of 89 patients were randomized to P4P and 92 to the FFS group. Patients’ average (SD) age was 63.0 (13.2) years, 49% were male and 76% were on antihypertensive drug therapy at baseline, taking a median of 2 (interquartile range = 1) medications. Mean systolic BP reductions in the P4P and FFS groups were 19.7 (SD = 18.4) vs 17.0 (SD = 16.4) mmHg, respectively (p = 0.47 for the comparison of deltas and p = 0.29 after multivariate adjustment). Conclusions: This trial of pharmacist prescribing found substantial reductions in systolic BP among poorly controlled hypertensive individuals but with no appreciable difference when pharmacists were paid by P4P vs FFS.","PeriodicalId":46612,"journal":{"name":"Canadian Pharmacists Journal","volume":"149 1","pages":"345 - 351"},"PeriodicalIF":1.5,"publicationDate":"2016-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1715163516671745","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"65467371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-08-09DOI: 10.1177/1715163516662670
L. Dolovich, Giulia P. Consiglio, L. Mackeigan, L. Abrahamyan, P. Pechlivanoglou, V. Rac, N. Pojskic, Elizabeth A. Bojarski, J. Su, M. Krahn, S. Cadarette
Background: MedsCheck Annual (MCA) is an Ontario government-funded medication review service for individuals taking 3 or more prescription medications for chronic conditions. Methods: This cohort study analyzed linked administrative claims data from April 1, 2007, to March 31, 2013. Trends in MCA claims and recipient characteristics were examined. Results: A total of 1,498,440 Ontarians (55% seniors, 55% female) received an MCA. One-third (36%) had 2 or more MCAs within 6 years. Service provision increased over time, with a sharper increase from 2010 onward. Almost half of Ontario pharmacies made at least 1 MCA claim in the first month of the program. Hypertension, respiratory disease, diabetes, psychiatric conditions and arthritis were common comorbidities. Recipients older than 65 years were most commonly dispensed an antihypertensive and/or antihyperlipidemic drug in the prior year and received an average of 11 unique prescription medications. Thirty-eight percent of recipients visited an emergency department or were hospitalized in the year prior to their first MCA. Discussion: Over the first 6 years of the program, approximately 1 in 9 Ontarians received an MCA. There was rapid and widespread uptake of the service. Common chronic conditions were well represented among MCA recipients. Older MCA recipients had less emergency department use compared with population-based estimates. Conclusions: Medication reviews increased over time; however, the number of persons receiving the service more than once was low. Service delivery was generally consistent with program eligibility; however, there are some findings possibly consistent with delivery to less complex patients.
{"title":"Uptake of the MedsCheck annual medication review service in Ontario community pharmacies between 2007 and 2013","authors":"L. Dolovich, Giulia P. Consiglio, L. Mackeigan, L. Abrahamyan, P. Pechlivanoglou, V. Rac, N. Pojskic, Elizabeth A. Bojarski, J. Su, M. Krahn, S. Cadarette","doi":"10.1177/1715163516662670","DOIUrl":"https://doi.org/10.1177/1715163516662670","url":null,"abstract":"Background: MedsCheck Annual (MCA) is an Ontario government-funded medication review service for individuals taking 3 or more prescription medications for chronic conditions. Methods: This cohort study analyzed linked administrative claims data from April 1, 2007, to March 31, 2013. Trends in MCA claims and recipient characteristics were examined. Results: A total of 1,498,440 Ontarians (55% seniors, 55% female) received an MCA. One-third (36%) had 2 or more MCAs within 6 years. Service provision increased over time, with a sharper increase from 2010 onward. Almost half of Ontario pharmacies made at least 1 MCA claim in the first month of the program. Hypertension, respiratory disease, diabetes, psychiatric conditions and arthritis were common comorbidities. Recipients older than 65 years were most commonly dispensed an antihypertensive and/or antihyperlipidemic drug in the prior year and received an average of 11 unique prescription medications. Thirty-eight percent of recipients visited an emergency department or were hospitalized in the year prior to their first MCA. Discussion: Over the first 6 years of the program, approximately 1 in 9 Ontarians received an MCA. There was rapid and widespread uptake of the service. Common chronic conditions were well represented among MCA recipients. Older MCA recipients had less emergency department use compared with population-based estimates. Conclusions: Medication reviews increased over time; however, the number of persons receiving the service more than once was low. Service delivery was generally consistent with program eligibility; however, there are some findings possibly consistent with delivery to less complex patients.","PeriodicalId":46612,"journal":{"name":"Canadian Pharmacists Journal","volume":"149 1","pages":"293 - 302"},"PeriodicalIF":1.5,"publicationDate":"2016-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1715163516662670","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"65466717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-08-08DOI: 10.1177/1715163516663693
L. Dolovich, R. Tsuyuki
You know that life as a pharmacist is busy. So many different activities to juggle—often all at the same time. There are multiple prescriptions to review and assess. There are medication reviews, immunizations, blood pressure or other services to organize, prioritize and provide. Patients or their family members want answers to questions about medications or health. Other health care providers need answers to medication questions that they have sent by phone, text or email. There are care plans to develop and case conferences to participate in. And this is just a partial list. How do you make sense of it all?
{"title":"Pharmacy practice research produces findings that inform how pharmacists contribute to optimal drug therapy outcomes for Canadians","authors":"L. Dolovich, R. Tsuyuki","doi":"10.1177/1715163516663693","DOIUrl":"https://doi.org/10.1177/1715163516663693","url":null,"abstract":"You know that life as a pharmacist is busy. So many different activities to juggle—often all at the same time. There are multiple prescriptions to review and assess. There are medication reviews, immunizations, blood pressure or other services to organize, prioritize and provide. Patients or their family members want answers to questions about medications or health. Other health care providers need answers to medication questions that they have sent by phone, text or email. There are care plans to develop and case conferences to participate in. And this is just a partial list. How do you make sense of it all?","PeriodicalId":46612,"journal":{"name":"Canadian Pharmacists Journal","volume":"149 1","pages":"261 - 263"},"PeriodicalIF":1.5,"publicationDate":"2016-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1715163516663693","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"65467251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-08-02DOI: 10.1177/1715163516662816
S. Levesque
With your recent coverage of the important work of pharmacists during natural disasters,1,2 I thought it would be an opportune time to update CPJ readers about a pharmacist organization that has spent decades working in areas around the world in greatest need of medical and pharmaceutical aid.
{"title":"Pharmacists without Borders Canada","authors":"S. Levesque","doi":"10.1177/1715163516662816","DOIUrl":"https://doi.org/10.1177/1715163516662816","url":null,"abstract":"With your recent coverage of the important work of pharmacists during natural disasters,1,2 I thought it would be an opportune time to update CPJ readers about a pharmacist organization that has spent decades working in areas around the world in greatest need of medical and pharmaceutical aid.","PeriodicalId":46612,"journal":{"name":"Canadian Pharmacists Journal","volume":"149 1","pages":"266 - 267"},"PeriodicalIF":1.5,"publicationDate":"2016-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1715163516662816","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"65466728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：